You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,302,002


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,302,002
Title:Etanercept formulations stabilized with combinations of sugars and polyols
Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Inventor(s): Manning; Mark (Johnstown, CO), Murphy; Brian (Fort Collins, CO)
Assignee: Coherus Biosciences, Inc. (Redwood City, CA)
Application Number:13/654,950
Patent Claims:1. A stable aqueous pharmaceutical composition comprising about 25 to about 75 mg/ml etanercept in combination with a stabilizer to reduce instability, aggregation misfolding and/or fragmentation of the etanercept during storage of the formulation; said stabilizer consisting of about 1 to about 10 wt. % sugar, about 1 mM to about 30 mM sodium phosphate and up to about 10 wt. % polyol, wherein said sugar and said polyol are different from each other, and wherein said formulation is free or essentially free of arginine.

2. The composition of claim 1 eliciting long term storage stability as characterized by at least one of: SEC analysis at M.sub.3 or T.sub.2 or T.sub.4 of: monomer content greater than about 90%; aggregates content of less than about 3 wt %; and fragment 3 content less than about 5 wt %: and HIC analysis at M.sub.3 or T.sub.2 or T.sub.4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt. %.

3. The composition of claim 1, comprising about 1 to about 10 wt. % sucrose, trehalose or dextrose; up to about 10 wt. % mannitol or sorbitol said composition having pH about 6.0 to 6.6; and wherein the composition is characterized by SEC analysis at M.sub.3 or T.sub.2 or T.sub.4 in which: the monomer content is greater than about 80 wt. %; aggregates content is less than about 3 wt. %, and fragment 3 content less than about 10 wt. %.

4. The composition of claim 3 eliciting long term storage stability characterized by: (a) an SEC analysis at M.sub.3 or T.sub.2 or T.sub.4 of greater than about 90 wt. % monomer content; and less than about 3 wt. % aggregate(s) content; and (b) an HIC analysis at M.sub.3 or T.sub.2 or T.sub.4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 4 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 80 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt. %.

5. The composition of claim 2 having an HIC analysis at M.sub.3 or T.sub.2 or T.sub.4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 1 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 95 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 3 wt. %.

6. The composition of claim 2 comprising: about 50 mg/ml of etanercept; about 1 to 5 wt. % sucrose, trehalose or dextrose; about 1-2 wt. % mannitol or sorbitol, about 10-30 mM sodium phosphate, said composition having pH of about 6.3 to 6.5.

7. The composition of claim 2 eliciting long term storage stability as characterized by: an HIC analysis at M.sub.3 or T.sub.2 or T.sub.4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to about 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt. %.

8. The composition of claim 2 having, at M.sub.3 or T.sub.2 or T.sub.4 no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 .mu.m.

Details for Patent 9,302,002

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL MINI etanercept Injection 103795 09/14/2017 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.